Objective: To evaluate the clinical efficacy and safety of quinidine in patients with KCNT1-related epilepsy of infancy with migrating focal seizures (EIMFS) in the infantile period and to compare with the effect of quinidine on mutant channels in vitro. Methods: We identified 4 patients with EIMFS with onset in the neonatal period, pathogenic variants in the KCNT1 gene, and lack of response to AEDs. Patients were prospectively enrolled, treated with quinidine, and monitored according to a predefined protocol. Electroclinical, neuroimaging, and genetic data were reviewed. Two patients had novel variants in the KCNT1 gene that were modeled in Xenopus oocytes with channel properties characterized using electrophysiology recordings. Results: Three of four patients were treated with quinidine early in their disease course, prior to 6 months of age. No significant side effects were noted with quinidine therapy. In addition, there were no significant changes in electroencephalography (EEG)-confirmed seizure burden during therapy, and patients had near hourly seizures before, during, and after treatment. Two patients had previously reported gain-of-function mutations, which demonstrated sensitivity to high levels of quinidine in the oocyte assay. Two patients with novel variants, showed characteristic gain-of-function and were thus predicted to be pathogenic. Of interest, these variants were essentially insensitive to high levels of quinidine. Significance: Patients had no reported benefit to quinidine therapy despite age at treatment initiation. Pharmacogenetic results in oocytes were consistent with clinical treatment failure in 2 patients, suggesting that single-dose pharmacologic assessment may be helpful in predicting which patients are exceedingly unlikely to achieve benefit with quinidine. In the 2 patients who had a lack of therapeutic benefit despite sensitivity to high concentrations of quinidine with in vitro oocyte assay, it is likely that the achievable exposure levels in the brain were too low to cause significant in vivo channel blockade.
| INTRODUCTION
Epilepsy of infancy with migrating focal seizures (EIMFS) is a severe early onset epileptic encephalopathy with high morbidity. Patients typically have seizure onset in the first 6 months of age, with a clinical course characterized by intractable epilepsy and severe intellectual disability. 1, 2 The most common cause are gain-of-function pathogenic variants in the KCNT1 gene, encoding a sodiumactivated potassium channel called Slack (sequence like a calcium-activated potassium channel). 3, 4 Activation of Slack results in K + efflux, contributing to the modulation of action-potential firing behaviour. 5 Enhanced Slack current seen in EIMFS patients could trigger epileptogenic firing properties by shortening action-potential duration and firing rate. [6] [7] [8] Variants in the KCNT1 gene are also associated with disparate epilepsy syndromes, including autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) as well as other focal epilepsies with variable phenotypes. 9, 10 However, variants found in patients with EIMFS cause more severe perturbations in channel conductance than in ADNFLE, up to 5 times greater than normal.
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Seizures in EIMFS are multifocal, prolonged, and arise independently and sequentially from both hemispheres, occur many times each day, and are refractory to nearly all conventional antiepileptic drugs. Some seizure control has been reported with potassium bromide or levetiracetam. [12] [13] [14] The discovery that the class I antiarrhythmic drug quinidine can reverse channel overactivity in vitro led to its rapid clinical application in a patient with EIMFS and an R428Q (c1283G>A, pArg428Gln) variant with reported in vivo efficacy. 11, 15 Subsequently, reductions in seizure frequency have been observed in few patients, some with functionally milder gain-of-function mutations in KCNT1, but treatment failures in other patients were also reported. [16] [17] [18] [19] [20] A dissociation with regard to in vitro efficacy of quinidine on potassium current and in vivo responsiveness has been noted, with a distinct patient with an R428Q variant demonstrating the least effective seizure reduction with quinidine. 17 These findings raise the question about determinants of responsiveness to quinidine, including phenotype, time from symptom onset to the initiation of treatment, or dose. Here, we report 4 patients with KCNT1-associated EIMFS, all with onset in the neonatal period, including 2 patients with novel variants. All patients were treated with quinidine according to a standardized protocol, including 2 patients treated before 2 months of age. We report on clinical safety and efficacy for all patients and in vitro efficacy for the 2 previously unreported mutations.
| METHODS

| Clinical characteristics
| Patient identification
Patients with the electroclinical phenotype of EIMFS and refractory to multiple antiepileptic drugs (AEDs) were identified at the participating centers. 1 As clinically indicated, patients underwent genetic testing with commercially available panels of common epilepsy-associated genes utilizing Sanger sequencing of genomic DNA. 21 Information was obtained directly from the referring physicians. The original clinical, ictal, and interictal video-electroencephalography (EEG), brain magnetic resonance imaging (MRI), and antiepileptic drug (AED) treatment of all patients were reviewed by pediatric neurologists and neurophysiologists (ALN, AD, MRC). Developmental delay and cognitive impairment were assessed using developmental milestones, current functioning, and neurologic examination. The degree of cognitive impairment was assessed qualitatively with a developmental quotient (DQ) based on acquisition of developmental milestones. The study was approved by the human research ethics committee of the University of California, San Francisco. Parents assented for off-label use of quinidine for the treatment of epilepsy.
| Quinidine treatment
Infants with EIMFS associated with KCNT1 variants (NM_ 020822.2) characterized by epileptic encephalopathy and intractable seizures were prospectively approached and trialed on quinidine using a standardized protocol. In brief, prior to quinidine initiation, patients were admitted to the cardiac step-down unit on continuous video-EEG and electrocardiography (ECG) telemetry, a standard 12-lead ECG was performed, and patients were given a test dose of
Key Points
• EIMFS can present in the neonatal period and is associated with gain-of-function pathogenic variants in the KCNT1 gene • Quinidine may reverse the effects of pathogenic KCNT1 variants in vitro • Quinidine has no impact in seizure burden in patients, even when trialed early in the course of the disease • Seizure frequency and severity improve with potassium bromide, but the long-term developmental prognosis remains unaltered quinidine of 2 mg/kg. During admission and prior to quinidine initiation, patients were evaluated with 24-hour video-EEG recording for determination of seizure type, frequency, and duration. Baseline complete blood count (CBC), complete metabolic panels, concomitant AED trough levels, and β-hydroxybutyrate when the ketogenic diet was co-administered were evaluated at baseline. After no side effects were reported to the initial test dose, patients were started on quinidine 15 mg/kg/d divided into 4 doses (maximum 200 mg/dose). Doses were escalated by 15 mg/kg/d at 14-16 day intervals up to a dose of 100 mg/kg/d, as tolerated, with the goal serum quinidine level between 2 and 5 mg/L. Prior to each dose increase, patients were admitted for inpatient video-EEG and ECG telemetry to reevaluate seizure burden. In 3 of 4 patients, blood was obtained during each admission for quinidine trough levels, concomitant AED trough levels, and β-hydroxybutyrate when the ketogenic diet was coadministered. A CBC and complete metabolic panel were obtained prior to and 24-48 hours after each dose escalation. Once on stable dosing of quinidine, patients were reevaluated with video-EEG and ECG telemetry every 3 months. All ECGs were reviewed by a board-certified pediatric cardiologist.
| Electrophysiology
| Oocyte preparation
Xenopus oocytes (Dumont stage V or VI) were surgically removed from Xenopus laevis and prepared as described previously. 22 Oocytes were kept in ND96 solution and stored at 17°C. Fifty nanoliters of capped complementary RNA (cRNA) was injected into each oocyte using the Roboocyte system (Multi Channel Systems, Reutlingen, Germany). A total of 10 ng of cRNA was injected into each oocyte.
| KCNT1 mutagenesis and in vitro transcription
A259D (c.776 C>A) and A259V (c.776 C>T) constructs were obtained from Genewiz in a Miniprep form. R1114W (c.3340 C>T) and Del550 (c.1649-1651delAGC, p. Gln550del) mutations were introduced into human KCNT1 expression construct 11 using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, California) according to the manufacturer's instructions. Construct fidelity for all 4 variants was confirmed by DNA sequencing. cDNAs were transcribed in vitro (mMessage mMachine; Ambion, Austin, Texas).
| Electrophysiology recordings
Two-electrode voltage-clamp recording was performed using the Roboocyte System (Multi Channel Systems) after 14-48 hours of expression. Electrodes containing 1.5 mol/L K-acetate and 0.5 mol/L KCl were used to impale oocytes that were held at −90 mV and perfused with bath solution containing (in millimolars) 96 NaCl, 2 KCl, 1.8 CaCl 2 , 1 MgCl 2 , and 5 HEPES, pH 7.5. Recording frequency was 1 kHz, and temperature was maintained between 20 and 22°C. To record expressed membrane currents, oocytes were held at −90 mV, and test depolarizations lasting for 1000 millisecond were applied at 10 mV increments, from −110 mV to +80 mV, at 5-second intervals. Contemporaneous measurement of wild-type (WT) KCNT1 currents was performed with the same batch of oocytes injected with variant KCNT1 messenger RNA (mRNA) to maintain an internal control of possible variability in expression from different batches of oocytes. Quinidine (Sigma, St. Louis, Missouri) was dissolved in ethanol to a concentration of 300 μmol/L and was perfused continuously to the oocytes for 1 minute, followed with 5-minute incubation. Currents were recorded before and after application.
The results obtained were compiled to depict functional differences of each variant (A259D, A259V, R1114W, and Q550del) and the effect of quinidine on A259D, R1114W, and Q550del in comparison to WT (and A259D vs A259V, Figure S1 ). Relative current traces, current voltage relationship curves and time to 50% peak curves were employed to determine functional differences between WT and mutants. To determine the effect of quinidine, in addition to relative current traces and current voltage relationship curves, the percent of remaining current for mutants (A259D, R1114W, and Q550del) and WT was evaluated, after exposure to the compound.
AxoGraph (AxoGraph Scientific, Sydney, Australia) was used to analyze the electrophysiologic data while statistical analysis was performed using Graphpad Prism 6 (GraphPad Software, La Jolla, California). Results are presented as a mean ± standard error of the mean. Statistical significance for current voltage relationship curves and time to 50% peak was determined using 2-way analysis of variance (ANOVA) with Bonferroni post hoc analysis, whereas Student t test was used to determine significant differences in percent of remaining current between WT and A259D mutant. One-way ANOVA with Bonferroni post hoc analysis was used to determine significant differences in percent of remaining current between WT, R1114W, and Q550del mutants.
| RESULTS
| Case descriptions
All patients had seizure onset in the neonatal period within 2 weeks of birth. No patient had pre-or perinatal risk factors for seizures, including evidence of hypoxic-ischemic encephalopathy. Seizures were initially focal and rapidly evolved into prolonged multifocal seizures. EEG was initially characterized by multifocal interictal epileptiform discharges, evolving into subcontinuous ictal discharges migrating from one region to another and from one brain hemisphere to another. Seizure duration was approximately 1-3 minutes and patients had multiple seizure per day. Most patient had clusters of multiple seizures per hours. Patients had failed several AEDs at the time of initiation of quinidine (Table 1 
| Quinidine therapy
There were no significant changes in seizure frequency and severity during therapy, with patients having >1-2 seizures per hour before, during, and after quinidine therapy. Quinidine therapy was stopped before reaching 100 mg/kg/d or a level of 2-5 mg/L in 3 of 4 cases due to perceived inefficacy ( Figure 1A ,B). There were no significant side effects noted during quinidine therapy. There were modest increases in QTc noted with prolonged therapy, although none reached criteria for prolonged QT ( Figure 1C ). Quinidine therapy increased trough levels of potassium bromide in one patient and decreased levels in another patient, in a dose-independent fashion. Patients on quinidine therapy receiving concomitant phenobarbital, carbamazepine, potassium bromide, or ketogenic diet therapy had no sustained alterations in AED trough levels/β-hydroxybutyrate (Table S1) . One patient had a 32%-37% decreases in levetiracetam levels over the course of quinidine therapy.
| Clinical follow-up
Patients have been followed for 12-24 months after quinidine initiation. At follow-up, one patient died at 15 months of age due to cardiac arrest. This patient had not received quinidine for >6 months and cause of death was presumed unrelated to quinidine. All other patients continued to have intractable epilepsy. Notably, in all patients, potassium bromide in add-on was associated with a decrease in seizure frequency in doses ranging from 50-80 mg/kg/d. All patients were diagnosed with profound developmental delay in keeping with the natural history of EIMFS. 25 Therefore, there were no significant changes in expected developmental trajectory, positive or negative, as a result of quinidine therapy. 
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| Quinidine sensitivity of KCNT1 variants
To investigate the sensitivity of KCNT1 variants to quinidine, the response to 300 μmol/L quinidine was measured in the oocyte assay. As reported previously, application of 300 μmol/L quinidine resulted in a significant reduction in current amplitudes of WT channels. In contrast, application of 300 μmol/L quinidine to the A259D diagnosis have improved our ability to convey prognosis, the model of precision medicine as it pertains to diseasespecific treatments in early onset epileptic encephalopathies remains challenging. In KCNQ2 and SCN2A encephalopathy, the use of sodium channel blockers can result in seizure freedom without substantial concomitant alterations in long-term neurodevelopmental prognosis, even when therapies are initiated within the first months of life. [27] [28] [29] In KCNT1-associated EIMFS, quinidine's action can effectively block the pathologic constitutive activation of the KCNT1 channel at the molecular level in some variants. 11 Clinical efficacy has been inconsistent. [15] [16] [17] Similar results have been noted with KCNT1-related autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). 30 In this case series of 4 patients with neonatal-onset EIMFS associated with KCNT1 pathogenic variants, quinidine therapy was safe, although it did not result in a reduction in clinical seizure frequency or duration and did not affect neurodevelopment. This is consistent with our in vitro Oocytes were held at −90 mV and stepped from −110 mV to +80 mV for 1000 msec every 5 s. Scale bars apply to all traces. B, Comparison of raw currentvoltage relationships of WT (n = 37) and A259D (n = 25), revealed significantly larger currents for the mutant (2-way ANOVA followed by Bonferroni post hoc analysis). C, Time to 50% peak of currents for WT (n = 28) and A259D (n = 13) exhibited significantly lower time for A259D mutant compared to WT channels (2-way ANOVA followed by Bonferroni post hoc analysis). *P < 0.1, **P < 0.01. E, Comparison of raw current-voltage relationships of WT (n = 37), R1114W (n = 25), and Del550 (n = 27), revealed significantly larger currents for the deletion mutant (2-way ANOVA followed by Bonferroni post hoc analysis). F, Time to 50% peak of currents for WT (n = 28) and R1114W (n = 11) exhibited no difference between both channels (2-way ANOVA followed by Bonferroni post hoc analysis). Time to 50% peak for Del550 mutant was not accurate due to quick activation of channel. *P < 0.1 NUMIS ET AL. Oocytes were held at −90 mV and stepped from −110 mV to +80 mV for 1000 ms every 5 s. Scale bars apply to all traces. B, Raw current-voltage relationships for WT (n = 37) and A259D (n = 15) before and after application of 300 μmol/L quinidine. Current amplitudes reduced significantly in WT and A259D channels (2-way ANOVA followed by Bonferroni post hoc analysis). C, Average remaining current at +80 mV of WT (n = 37) and A259D (n = 15) human KCNT1 channels after application of 300 μmol/L quinidine showed significant difference between WT and A259D channels (unpaired t test). *P < 0.1, **P < 0.01. E, Raw current-voltage relationships for WT (n = 37), R1114W (n = 16) and Del550 (n = 14) before and after application of 300 μmol/L quinidine. Current amplitudes reduced significantly in WT and R1114 channels with exposure to quinidine (2-way ANOVA followed by Bonferroni post hoc analysis). F, Average remaining current at +80 mV of WT (n = 37), R1114W (n = 16), and Del550 (n = 14) hKCNT1 channels after application of 300 μmol/L quinidine revealed significant differences between WT, R1114W, and Del550 (1-way ANOVA followed by Bonferroni post hoc analysis). *P < 0.1, **P < 0.01 results of variants from Patients 1 and 2 that harbored Q550del and A259D, which were essentially insensitive to even high doses of quinidine. This is an important finding that has implications for future drug discovery, as disease variants could have a range of sensitivity to novel or other repurposed medications. Patients harboring drug-insensitive mutations are unlikely to achieve much therapeutic benefit, and such assays should be incorporated in future precision medicine applications in KCNT1-positive EIMFS. Patients 3 and 4 harbored mutations that displayed in vitro sensitivity to 300 μmol/L quinidine yet failed to derive any therapeutic benefit. This apparent mismatch in the in vitro and in vivo response of quinidine therapy may be explained by target-specific tissue concentrations. Quinidine penetrates across the blood-brain barrier, with levels varying between 9% and 46% of unbound plasma levels. 31, 32 After a therapeutic dose of quinidine is administered orally, cerebrospinal fluid concentrations range from 9-15 nmol/L. In modeled human KCNT1 mutants, 300 μmol/L is necessary to produce a significant block.
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The clinical inefficacy we observed may then be due to inadequate tissue concentrations. We targeted serum quinidine levels to established therapeutic levels of 2-6 μg/mL. Toxicity can arise at any dose, but certainly at serum levels above 9 μg/mL. Therefore, further increases in serum levels are unlikely to result in adequate target tissue concentrations without significant cardiovascular side effects. Coupled with our poor appreciation of the extent of KCNT1 blockade needed for clinical benefit, it is not surprising that quinidine was ineffective. A better understanding of exposure and necessary receptor occupancy may tailor future in vitro assays to assess the efficacy of novel therapeutics at lower concentration ranges and to predict clinical efficacy in patients with KCNT1 variants. Prior case series have described patients with seizure onset in the neonatal period in KCNT1-associated EIMFS, although only one case has been diagnosed so early on in the disease course. 18 All patients in this series initiated quinidine therapy at an early age, with 2 patients initiating therapy within the first 2 months of life. [15] [16] [17] [18] 33 Despite early targeting of the pathologic channel, no disease-modifying effects were noted in the clinical phenotype. In contrast to previous hypotheses, our data do not support "age at quinidine initiation" as a variable that can modify overall outcome. 19 Perhaps then, single gene mutations cause more widespread problems that targeted therapy even when initiated at an early age in development cannot overcome. Although targeting of the KCNT1 channel with quinidine in EIMFS did not provide benefit, genomic-guided therapy with potassium bromide may ameliorate the epileptic phenotype in this population. Consistent with prior series, all patients here who received potassium bromide were noted to have reductions in seizure frequency and severity. 12, 13 Although as in KCNQ2 encephalopathy and SCN2A encephalopathy, we do not anticipate bromides to ultimately affect long-term neurodevelopmental prognosis. The precise mechanism of hyperexcitability driven by mutations in the KCNT1 gene remains unknown. Does quinidine therapy then truly target the deleterious effects resulting in the epileptic phenotype? The KCNT1 protein contains a long C-terminal domain allowing for interactions with numerous cytosolic proteins including the protein kinase C (PKC) and fragile-x mental retardation (FRMP) proteins, which independently increase the likelihood of channel opening. 34, 35 We are in need of novel therapeutic strategies that either more specifically target disease genes or impact the network scale changes seen in the early onset epileptic encephalopathies. Early and effective diagnosis, with detailed electroclinical phenotyping and genetic testing, still yields the best chances of targeted therapy in a window where we can truly exert changes to neurodevelopment. However, this relationship is undoubtedly complex.
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